Introduction: Effective coordination between hospitals and community-based providers is essential to support home-based care for older adults with cancer. We previously identified six key domains of effective coordination-system infrastructure, information exchange, communication, timeliness, human resource development, and information dissemination-highlighting anticipatory and relational elements. However, their nationwide implementation across care settings remains unclear. This study aimed to clarify the implementation status of coordination practices across these domains and to identify inter-institutional gaps among hospitals and community-based providers. Materials and methods: We conducted a nationwide cross-sectional survey (July-September 2025) targeting all designated cancer care hospitals (DCHs; n = 463), randomly selected home visit medical facilities (HVMFs; n = 1500), and long-term care management agencies (LTCMAs; n = 1500). Implementation of Best Practice items was assessed using a 5-point Likert scale. Rates >= 75% were classified as Higher Implementation and <75% as Lower Implementation; differences of >= 20% were defined as inter-institutional gaps. Results: A total of 1156 institutions responded (209 DCHs, 315 HVMFs, and 632 LTCMAs; response rate 33.4%). Across domains, implementation was higher for system infrastructure and information exchange related to discharge and inpatient care, whereas communication, timeliness, human resource development, and information dissemination were lower, particularly in outpatient and anticipatory phases. Discharge-or crisis-triggered processes, including standardized documentation, inpatient biomedical information exchange, and urgent communication, were classified as Higher Implementation. In contrast, outpatient-phase coordination, sharing of advance care planning (ACP) and contextual information, information and communication technology (ICT)enabled bidirectional communication, post-transition feedback, workforce development, and patient-facing information dissemination were classified as Lower Implementation. Inter-institutional gaps >20% were common at the hospital-community interface, especially between DCHs and LTCMAs in ACP and contextual information sharing, and between DCHs and HVMFs in ICT-based communication and post-transition feedback. Discussion: While discharge and crisis-response coordination for older adults with cancer in Japan is well-established, gaps remain in anticipatory, contextual, and bidirectional domains. These findings suggest that management for this population, which requires integration of oncologic, functional, and psychosocial care, is predominantly transition-triggered rather than trajectory-based. In aging societies such as Japan, strengthening anticipatory engagement and relational integration across medical and long-term care sectors will be critical to achieving person-centered home-based cancer care.
This study reports on analytical and clinical validation of the highly automated Ion Torrent™ Oncomine™ Dx Express Test (ODxET) for detecting PIK3CA / AKT1 / PTEN -altered tumors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer that may benefit from treatment with capivasertib plus fulvestrant. Analytical validation studies were completed using commercially sourced breast cancer tissue specimens to establish the ODxET assay detection capability (limit of detection, limit of blank), precision (repeatability, reproducibility), and effect of endogenous interfering substances for detecting PIK3CA / AKT1 / PTEN alterations. Clinical validation was performed using 429 residual breast cancer tissue samples from the Phase 3 CAPItello-291 trial and progression-free survival (PFS) was analyzed for patients with PIK3CA / AKT1 / PTEN -altered tumors, as detected by ODxET, and compared to efficacy outcomes from the CAPItello-291 study. Comparison of assay agreement between ODxET and FoundationOne®CDx (F1CDx) gave an overall, positive and negative percent agreement of 89.2%, 82.0%, and 96.6%, respectively. The 18% false negative rate observed with ODxET was largely attributable to limited detection of complex PTEN variants. PFS benefit was observed with capivasertib plus fulvestrant versus placebo plus fulvestrant in patients with PIK3CA / AKT1 / PTEN -altered tumors detected by ODxET ( n =162; hazard ratio 0.55, 95% confidence interval [CI]: 0.38–0.78). This is similar to the observed PFS benefit in the population with PIK3CA / AKT1 / PTEN -altered tumors identified by F1CDx in the CAPItello-291 trial (hazard ratio 0.49, 95% CI: 0.38–0.64). This study demonstrates the clinical utility of ODxET to identify patients with PIK3CA / AKT1 / PTEN -altered tumors that may benefit from treatment with capivasertib plus fulvestrant.
This study reports on analytical and clinical validation of the highly automated Ion Torrent™ Oncomine™ Dx Express Test (ODxET) for detecting PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer that may benefit from treatment with capivasertib plus fulvestrant.Analytical validation studies were completed using commercially sourced breast cancer tissue specimens to establish the ODxET assay detection capability (limit of detection, limit of blank), precision (repeatability, reproducibility), and effect of endogenous interfering substances for detecting PIK3CA/AKT1/PTEN alterations. Clinical validation was performed using 429 residual breast cancer tissue samples from the Phase 3 CAPItello-291 trial and progression-free survival (PFS) was analyzed for patients with PIK3CA/AKT1/PTEN-altered tumors, as detected by ODxET, and compared to efficacy outcomes from the CAPItello-291 study.Comparison of assay agreement between ODxET and FoundationOne®CDx (F1CDx) gave an overall, positive and negative percent agreement of 89.2%, 82.0%, and 96.6%, respectively. The 18% false negative rate observed with ODxET was largely attributable to limited detection of complex PTEN variants. PFS benefit was observed with capivasertib plus fulvestrant versus placebo plus fulvestrant in patients with PIK3CA/AKT1/PTEN-altered tumors detected by ODxET (n=162; hazard ratio 0.55, 95% confidence interval [CI]: 0.38–0.78). This is similar to the observed PFS benefit in the population with PIK3CA/AKT1/PTEN-altered tumors identified by F1CDx in the CAPItello-291 trial (hazard ratio 0.49, 95% CI: 0.38–0.64). This study demonstrates the clinical utility of ODxET to identify patients with PIK3CA/AKT1/PTEN-altered tumors that may benefit from treatment with capivasertib plus fulvestrant.
Lung cancer is one of the malignancies for which new clinical evidence has accumulated most rapidly in recent years. In parallel with advances in systemic therapy, radiotherapy has also evolved substantially with the development of high-precision techniques such as stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy, and particle therapy. These technological innovations, together with the introduction of immunotherapy and targeted therapies, have reshaped the role of radiotherapy within multidisciplinary treatment strategies for non-small cell lung cancer (NSCLC). This review summarizes current clinical practice and emerging perspectives in radiotherapy for NSCLC across disease stages. In early-stage disease, the established role of SBRT and the potential advantages of particle therapy as curative strategies for medically inoperable patients and for operable patients who refuse surgery are outlined. For locally advanced NSCLC, evolving treatment paradigms in the era of immunotherapy are reviewed, including concurrent chemoradiotherapy followed by consolidation immunotherapy, as well as ongoing efforts to reduce treatment-related toxicity through advances in radiotherapy techniques. In addition, the emerging role of radiotherapy as local consolidative therapy for oligometastatic stage IV NSCLC is highlighted, with attention to recent randomized trials and the challenges of patient selection. As treatment strategies for NSCLC continue to evolve rapidly, radiotherapy is expected to play an increasingly important role in multidisciplinary management. Further research is required to optimize treatment sequencing, identify patients most likely to benefit from radiotherapy, and refine its integration with modern systemic therapies. Radiotherapy remains a key component of multidisciplinary management for non-small cell lung cancer (NSCLC). This review summarizes current clinical evidence and the evolving roles of radiotherapy across disease stages, including early-stage, locally advanced, and oligometastatic NSCLC.